VCM Analyzer
Novel VCM showed correlation between clotting time and unfractionated heparin (UFH) superior to “gold standard” aPTT method in single-center study
Providing clinicians with diagnostic tools that simplify the monitoring of critically ill patients is crucial to improving outcomes during the COVID-19 pandemic”
— John B. Mowell, Entegrion Chairman and Executive Director
DURHAM, NC, U.S., January 5, 2021 /EINPresswire.com/ -- Entegrion, Inc., a leading developer of innovative solutions for clinical diagnosis and management of hemostasis, highlighted a newly released publication of a single-center study demonstrating the clinical value of its portable Viscoelastic Coagulation Monitor (VCM) as a novel device to assess coagulation at the bedside. In the study, published in the Online First section of the ASAIO Journal, UFH dose was better correlated with the VCM than with Activated Partial Thromboplastin Time (aPTT), considered the “gold standard” for UFH monitoring. The VCM bears the CE mark for use in Europe, and is available for research use only in the U.S.